Sign In
Free Newsletter
J&J to acquire cancer drug developer Ambrx for $2B
According to the New Brunswick-based buyer, the addition of the clinical-stage biopharmaceutical company presents a distinct opportunity to design, develop and commercialize targeted oncology therapeutics.
Sanofi partners with Janssen, Teva on E. coli, IBD treatments
The global health care company will pay a cumulative $675 million in upfront costs for the collaborations.
Johnson & Johnson unveils new look
Along with the revamped brand and visual identity, the New Brunswick-based health care giant also said it will eventually rename its Janssen pharmaceutical segment.
NJ drugmakers’ products among first targeted for Medicare price negotiations
Pharmaceutical companies, including Merck, Johnson & Johnson and others, are concerned the move will hamper innovation and impede patient access and choice.
J&J permits Aspen to produce Janssen COVID vaccine under own name
The agreement marks the first inoculation for the virus to be manufactured and made available by an African company for people living in Africa.
